This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Lynparza
  • /
  • Olaparib Treatment in Relapsed Breast Cancer Susce...
Clinical trial

Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

Read time: 1 mins
Last updated:21st Jan 2021
Status: Active, not recruiting
Identifier: NCT02282020
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest